MGRM (Monogram Orthopedics) נכסים נקיים של החברה

Monogram Technologies (MGRM) is minimizing production disruption risks by expanding its list of titanium and electronics suppliers. Profit growth is expected following FDA approval of robotic systems for bone surgery, which is reflected in the price action, where the indicator stands at 0.01. Monogram Technologies (MGRM) generates revenue through the sale of unique surgical robots with patient-specific customization, enabling the company to implement premium pricing and mandatory service contracts.

Assessing the asset quality of Monogram Technologies (MGRM) requires an analysis of its equity structure. The dynamics of the company's net assets reflect the difference between total liabilities and the value of all resources. This metric measures the real value of the business, net of debt, and reacts to borrowing costs. For this AI systems developer, such capital provides protection for its patent moat. A high level of this indicator guarantees stability when scaling sales of high-margin implants.